#Immunotherapy #HX044 #Hanx Biopharmaceuticals

Hanx Biopharmaceuticals' Innovative Step in Cancer Treatment

On December 30, 2024, Hanx Biopharmaceuticals, Co. Ltd., an innovative biotechnology firm focusing on cutting-edge immunotherapies, achieved a significant milestone by administering the first dose to a patient in Australia as part of their Phase 1 clinical trial for HX044. This clinical trial, officially designated as HX044-I-01, is aimed at evaluating the safety, tolerability, pharmacokinetics, and initial efficacy of this promising new therapy in patients suffering from advanced solid tumors.

Understanding HX044

HX044 is a groundbreaking bispecific antibody developed in-house by Hanx Biopharmaceuticals. This treatment stands out as a first-in-class therapy, specifically designed to target a variety of malignant tumors that exhibit resistance to current therapies, particularly those targeting the PD-1 pathway. Such tumors include non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma, and certain gastrointestinal cancers.

This bispecific antibody introduces a novel approach to CTLA-4 immunotherapy, aiming to broaden the therapeutic window, optimize safety, and boost antitumor immune responses in patients. The innovative design of HX044 enhances its effectiveness even against